Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Restorative Gel Could Help Reverse Paralysis

By BiotechDaily International staff writers
Posted on 28 May 2013
A biodegradable implant that delivers a therapeutic gel could help restore healthy nerve function in degenerative disorders such as Parkinson's disease.

Researchers at Tel Aviv University (Israel) developed the implant, which is a soft, biodegradable tube that serves as a physical bridge to help the nerve ends connect. Lining the inside of the biodegradable tube is a guiding regeneration gel (GRG), a transparent, highly viscous, malleable, and adaptable gel that increases nerve growth and healing, helping the severed nerve ends to rejoin. But the GRG not only aids reconnection and cell preservation, it can also support their survival while being used for therapy and transplantation.

The key to the regeneration process lies in the composition of the gel, with three main components: superoxide dismutase (SOD) antioxidants, which exhibit high anti-inflammatory activities; synthetic laminin-derived peptides, which act as a railway or track for the nerve fibers to grow along; and hyaluronic acid, commonly found in the human fetus, which serves as a buffer against drying, a major danger for most implants. These components allow the nerve to heal the way a fetus does in the womb - quickly and smoothly.

Research to-date has shown that GRG stimulates cell growth, neuronal sprouting, and extracellular matrix (ECM) formation, supporting cells in vitro and in vivo upon implantation. It also supports three dimensional (3D) growth and differentiation of various cell types (embryonic, adult stem cells, and preneuronal cells). The implications for therapeutic applications include peripheral nerves reconstruction, cell therapy, corneal preservation, wound healing, and as a postirradiation tissue cavity filler.

“The implant has already been tested in animal models, and the gel by itself can be used as a stand-alone product, acting as an aid to cell therapy,” said GRG codeveloper Shimon Rochkind, MD. “When grown in the gel, cells show excellent development, as well as intensive fiber growth. This could have implications for the treatment of diseases such as Parkinson's.”

Related Links:

Tel Aviv University



Channels

Genomics/Proteomics

view channel
Image: Nomarski interference contrast photomicrographs of Cryptosporidium in the feces of an HIV-positive human (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).

Advanced Genetic Tools Revamp Search for Drugs to Treat Cryptosporidium

Genetically engineered modifications to genome of the diarrhea-causing parasite Cryptosporidium are expected to expedite research towards vaccine and drug development to prevent or cure infection by this pathogen.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.